RE:RE:RE:Newsletter out
enriquesuave wrote: An extra 2 patients who are showing negative cystoscopy but positive cytology are still pending as UUTUC has not yet been ruled out and may be CR as well. Looks like they are aiming to start a trial for both GBM and NSCLC as that would make sense if they are using X-ray activation. We will hear of preclinical animal data before. IMO. The hospitals are screening new patients hopefully November- December we get to see a decent pace of treatments.
We could still possibly have a 42% CR...not bad for all having been under treated. Also, the 4 patients that had been withdrawn from the study due to not showing a response (based on the original/more stringent protocol) would have been eligible for a 2nd treatment based on the updated protocol...all 4 had shown stable disease (no disease progression). So "92%" of patients (vs 58%) would have otherwise been eligible for a 2nd treatment...despite all being under treated. That's pretty remarkable & bodes very well for our 1 yr interim data, considering they will be receiving optimized/proper doses for their 2nd treatments...& we all know how Ph 1 patients performed after "one" optimized treatment.
Based on the above, it's certainly not unreasonable to anticipate >67% 1 yr CRs. Still very comfortable/confident that the science will win the day. Riches should be awaiting us despite the company leaving money on the table...& giving a good portion away.